Literature DB >> 21792648

Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward.

Ayman El Garf1, Bassel El Zorkany, Rasha Gheith, Hala Sheba, Geilan Abdel Moneim, Kamal El Garf.   

Abstract

To study the prevalence of anti-HCV antibodies among patients admitted to the rheumatology department, Cairo University hospitals, in 6-month period as well as to determine whether chronic HCV infection was the primary cause of their admission or just a concomitant association with the rheumatic disease. One hundred and fifty-seven patients were included in this study. They represent all patients admitted to the rheumatology inpatient department of Cairo University hospitals during the study period. Preset questionnaire including detailed demographic data, cause of admission and clinical manifestations of their disease was obtained for every patient. All patients were screened for HCV antibodies using ELISA technique. Other laboratory and imaging investigations were done according to the patient's diagnosis. Twenty-nine patients (18.5%) were positive for HCV antibody. Eleven patients of them (38%) were admitted due to rheumatic manifestations directly related to chronic HCV infection, which represent 7% of all admitted patients (11/157). HCV antibodies were found in 17.6 and 6.7% among patients with rheumatoid and systemic lupus erythematosus. Arthritis, palpaple purpura, digital gangrene and mononeuritis multiplex were the most common causes of admission related to chronic HCV infection. HCV antibodies were found in 18.5% among admitted patients to the rheumatology ward. The rheumatic manifestations of chronic HCV represent the primary cause of admission in 7% of all admitted patients. HCV screening should be included in the routine investigations for patients presenting to rheumatology departments in countries with high prevalence of chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21792648     DOI: 10.1007/s00296-011-2014-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  38 in total

1.  Hepatitis B and C viruses serology in patients with SLE.

Authors:  M Abu-Shakra; S El-Sana; M Margalith; E Sikuler; L Neumann; D Buskila
Journal:  Lupus       Date:  1997       Impact factor: 2.911

2.  Hepatitis C virus infection in a hematology ward: evidence for nosocomial transmission and impact on hematologic disease outcome.

Authors:  Enrico Silini; Anna Locasciulli; Luca Santoleri; Livio Gargantini; Giovanbattista Pinzello; Marco Montillo; Luciana Foti; Antonella Lisa; Nicola Orfeo; Enrico Magliano; Annamaria Nosari; Enrica Morra
Journal:  Haematologica       Date:  2002-11       Impact factor: 9.941

Review 3.  Hepatitis C virus transmission in a pediatric oncology ward: analysis of an outbreak and review of the literature.

Authors:  A Knöll; M Helmig; O Peters; W Jilg
Journal:  Lab Invest       Date:  2001-03       Impact factor: 5.662

4.  Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C.

Authors:  P Cacoub; C Renou; E Rosenthal; P Cohen; I Loury; V Loustaud-Ratti; A M Yamamoto; A C Camproux; P Hausfater; L Musset; P Veyssier; G Raguin; J C Piette
Journal:  Medicine (Baltimore)       Date:  2000-01       Impact factor: 1.889

5.  Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey.

Authors:  M A Nafeh; A Medhat; M Shehata; N N Mikhail; Y Swifee; M Abdel-Hamid; S Watts; A D Fix; G T Strickland; W Anwar; I Sallam
Journal:  Am J Trop Med Hyg       Date:  2000 Nov-Dec       Impact factor: 2.345

6.  Role of hepatitis C infection in chronic liver disease in Egypt.

Authors:  G Thomas Strickland; Hanaa Elhefni; Tary Salman; Imam Waked; Mohamed Abdel-Hamid; Nabiel Nh Mikhail; Gamal Esmat; Alan Fix
Journal:  Am J Trop Med Hyg       Date:  2002-10       Impact factor: 2.345

7.  Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.

Authors:  B D Pryor; S G Bologna; L E Kahl
Journal:  Arthritis Rheum       Date:  1996-09

8.  Seroprevalence of HIV and HCV infections in Alexandria, Egypt.

Authors:  I Quinti; E Renganathan; E El Ghazzawi; M Divizia; G Sawaf; S Awad; A Pana; G Rocchi
Journal:  Zentralbl Bakteriol       Date:  1995-12

9.  Hepatitis B and C in Juba, southern Sudan: results of a serosurvey.

Authors:  M C McCarthy; A el-Tigani; I O Khalid; K C Hyams
Journal:  Trans R Soc Trop Med Hyg       Date:  1994 Sep-Oct       Impact factor: 2.184

Review 10.  Extrahepatic manifestations of hepatitis C virus.

Authors:  Richard K Sterling; S Bralow
Journal:  Curr Gastroenterol Rep       Date:  2006-02
View more
  5 in total

1.  Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis.

Authors:  Bassel El-Zorkany; Abir Mokbel; Sherif M Gamal; Maha Mousa; Mohamed Youssef; Ihsane Hmamouchi
Journal:  Clin Rheumatol       Date:  2015-12-15       Impact factor: 2.980

2.  Hepatitis C virus infection and its rheumatologic implications.

Authors:  Zeynel A Sayiner; Uzma Haque; Mohammad U Malik; Ahmet Gurakar
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-05

3.  Chronic hepatitis C viral infection among SLE patients: the significance of coexistence.

Authors:  Naim Mahroum; Ashraf Hejly; Shmuel Tiosano; Omer Gendelman; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

4.  Role of LncRNA-AF085935, IL-10 and IL-17 in Rheumatoid Arthritis Patients With Chronic Hepatitis C.

Authors:  Dina Sabry; Azza Elamir; Rania Hosny Mahmoud; Ahmed Ali Abdelaziz; Wael Fathy
Journal:  J Clin Med Res       Date:  2017-04-01

Review 5.  Hepatitis C virus viremic rate in the Middle East and North Africa: Systematic synthesis, meta-analyses, and meta-regressions.

Authors:  Manale Harfouche; Hiam Chemaitelly; Silva P Kouyoumjian; Sarwat Mahmud; Karima Chaabna; Zaina Al-Kanaani; Laith J Abu-Raddad
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.